Germany · Delayed Price · Currency is EUR XTL Biopharmaceuticals Statistics
Total Valuation
FRA:H2K2 has a market cap or net worth of EUR 5.68 million. The enterprise value is 5.52 million.
| Market Cap | 5.68M |
| Enterprise Value | 5.52M |
Important Dates
The next estimated earnings date is Thursday, March 12, 2026.
| Earnings Date | Mar 12, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +54.39% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 45.39% |
| Owned by Institutions (%) | 2.66% |
| Float | 516.75M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 6.89 |
| PB Ratio | -141.85 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -1.03 |
| EV / Sales | 6.20 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.70
| Current Ratio | 0.70 |
| Quick Ratio | 0.46 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -119.78 |
Financial Efficiency
Return on equity (ROE) is -577.13% and return on invested capital (ROIC) is -329.50%.
| Return on Equity (ROE) | -577.13% |
| Return on Assets (ROA) | -240.56% |
| Return on Invested Capital (ROIC) | -329.50% |
| Return on Capital Employed (ROCE) | 12,742.40% |
| Revenue Per Employee | 82,425 |
| Profits Per Employee | -537,126 |
| Employee Count | 10 |
| Asset Turnover | 0.62 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -297,174 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -70.45% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -70.45% |
| 50-Day Moving Average | 0.69 |
| 200-Day Moving Average | 0.96 |
| Relative Strength Index (RSI) | 38.49 |
| Average Volume (20 Days) | 730 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, FRA:H2K2 had revenue of EUR 824,252 and -5.37 million in losses. Loss per share was -0.01.
| Revenue | 824,252 |
| Gross Profit | -1.92M |
| Operating Income | -5.10M |
| Pretax Income | -5.67M |
| Net Income | -5.37M |
| EBITDA | n/a |
| EBIT | -5.10M |
| Loss Per Share | -0.01 |
Balance Sheet
The company has 220,539 in cash and 73,229 in debt, with a net cash position of 147,310.
| Cash & Cash Equivalents | 220,539 |
| Total Debt | 73,229 |
| Net Cash | 147,310 |
| Net Cash Per Share | n/a |
| Equity (Book Value) | -40,021 |
| Book Value Per Share | -0.00 |
| Working Capital | -194,142 |
Cash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | -232.85% |
| Operating Margin | -618.70% |
| Pretax Margin | -687.71% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
FRA:H2K2 does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -54.39% |
| Shareholder Yield | -54.39% |
| Earnings Yield | -94.61% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on February 10, 2017. It was a reverse split with a ratio of 0.2.
| Last Split Date | Feb 10, 2017 |
| Split Type | Reverse |
| Split Ratio | 0.2 |
Scores
FRA:H2K2 has an Altman Z-Score of -333.7. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -333.7 |
| Piotroski F-Score | n/a |